Whelan Jeremy, Seddon Beatrice, Perisoglou Martha
Department of Oncology, University College Hospital, 250 Euston Road, London NW1 2PG, UK.
Curr Treat Options Oncol. 2006 Nov;7(6):444-55. doi: 10.1007/s11864-006-0020-y.
Improving cure rates for osteosarcoma continues to be a major challenge. The clinical management of individual patients is exacting and requires a skilled, experienced team including a surgeon, pathologist, oncologist, and radiologist, with support from specialist nurses and rehabilitation teams. Outcomes from treatment have improved little in 20 years and remain disappointing. Chemotherapy for osteosarcoma is among the most grueling of any given for solid tumors, and treatment of the primary tumor is associated with permanent disability of some degree in a significant proportion of patients. New systemic treatments remain beyond the horizon. In recognition of these difficulties, an international cooperation has begun with the opening of a randomized trial, European and American Osteosarcoma (EURAMOS) 1, in Europe and the United States. This study heralds a new era of clinical investigation into osteosarcoma, with the promise of valuable biologic insights and rapid evaluation of investigational strategies. Osteosarcoma should always be treated under the guidance of a specialist team, and we recommend that whenever possible, patients be offered entry into EURAMOS 1 or other well-designed clinical trials.
提高骨肉瘤的治愈率仍然是一项重大挑战。对个体患者的临床管理要求严苛,需要一个技术娴熟、经验丰富的团队,包括外科医生、病理学家、肿瘤学家和放射科医生,同时还需要专科护士和康复团队的支持。二十年来,治疗效果几乎没有改善,仍然令人失望。骨肉瘤的化疗是实体瘤化疗中最折磨人的之一,在相当一部分患者中,原发性肿瘤的治疗会导致某种程度的永久性残疾。新的全身治疗方法仍遥遥无期。认识到这些困难后,欧洲和美国开展了一项随机试验——欧美骨肉瘤(EURAMOS)1,开启了国际合作。这项研究预示着骨肉瘤临床研究的新时代,有望获得宝贵的生物学见解并快速评估研究策略。骨肉瘤应始终在专业团队的指导下进行治疗,我们建议只要有可能,就应让患者参与EURAMOS 1或其他精心设计的临床试验。